Perforation Of Cornea — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for perforation of cornea. 49 active patents protecting 3 drugs from 3+ originators. First major cliff: 2027. Daily refresh.

3
Approved drugs
49
Active US patents
53/100
Avg vulnerability
—
Annual revenue covered

Originators in Perforation Of Cornea

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 32 patents Generic (originally Merck) 15 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating perforation of cornea. Each bar = one year. Y-axis scaled to peak year (30 patents).

2
27
2
28
3
30
1
32
30
33
3
34
3
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lotemax
LOTEPREDNOL ETABONATE
 Bausch Health 32 42 — 2033-05-03
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8869794 Tobi method of use 75 2028-09-12
10207066 Tobi method of use 68 2030-11-04
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03
12115246 Lotemax method of use 58 2033-05-03
12115246 Lotemax method of use 58 2033-05-03
12150896 Decadron method of use 58 2036-10-07
12144889 Decadron method of use 58 2041-04-26
11596599 Lotemax method of use 53 2033-05-03
11219597 Lotemax method of use 53 2033-05-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
9393213 Lotemax formulation 25 2033-05-03
10688045 Lotemax formulation 25 2033-05-03
10646436 Lotemax formulation 25 2033-05-03
10646437 Lotemax formulation 25 2033-05-03
9393213 Lotemax formulation 25 2033-05-03
10688045 Lotemax formulation 25 2033-05-03
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14

Related